Biomerica

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.

IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced certain preliminary financial results for the second fiscal quarter ended November 30, 2021. All figures in this release are approximate due to the preliminary nature of this announcement.

Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million

IRVINE, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that Dr. Brooks Cash, one the nation's most recognized leaders in Gastroenterology medicine, has agreed to chair Biomerica's newly formed Colorectal Cancer Scientific Advisory Board (“SAB”). The SAB will guide and help expand the use of the EZ Detect product in Colorectal Cancer screenings and reaching underserved patient populations. Other key opinion leaders in the Gastroenterology field will be joining Dr. Cash on this SAB.

Biomerica Forms Scientific Advisory Board for Colorectal Cancer Screening

IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today announced that the Canadian Patent Office has issued a notice of allowance for Biomerica's patent application pertaining to the Company's InFoods® diagnostic guided therapy platform technology that offers a novel approach in the treatment of patients suffering from Irritable Bowel Syndrome (“IBS”). IBS is a chronic, often debilitating, functional gastrointestinal (“GI”) disorder with symptoms that include abdominal pain, bloating, and altered bowel behaviors, such as constipation and/or diarrhea, or alternating between the two.

Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment

IRVINE, Calif. , Oct. 29, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that in conjunction with Breast Cancer Awareness month, which takes place each October, it has launched its new website for the Aware® at-home breast self-exam pad. Breast cancer is the most commonly-diagnosed cancer in women.   In 2021, an estimated 281,550 new cases of invasive breast cancer will be diagnosed and approximately 43,600 women will die from breast cancer in US.    One in eight women will develop invasive breast cancer in their lifetime.

Biomerica Launches New Website for Its Aware® Breast Exam Device

Biomerica(NASDAQ:BMRA) stock rose by 2.53% on Monday after the company reported its Q1 earnings results on Friday, October 15, 2021 at 06:30 AM. Here's what investors need to know about the announcement.

Recap: Biomerica Q1 Earnings

IRVINE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that Walmart has begun in-store sales and rollout of the Company's EZ Detect™ colorectal disease screening test within the nationwide Walmart retail system. Biomerica has shipped the EZ Detect product to Walmart distribution centers in the US and product is projected to be on the shelf in over 4,600 Walmart Stores nationwide over the next two weeks. The in-store retail placement follows Biomerica's previous announcement in early October, that Walmart had begun sales of EZ Detect™ product for online purchase through Walmart.com (https://www.walmart.com/ip/EZ-Detect-Colon-Disease-Test-Kit/577079744). As part of its ongoing sales strategy, the Company has hired an internal digital and social media team to increase its presence on all major social communication platforms (Instagram: https://bit.ly/3j5FYDB; Facebook: https://bit.ly/3aBJBfN;   Twitter: https://bit.ly/3BNROJW), and to promote awareness for its at-home testing products. In addition, Biomerica is in negotiations with several large partners for distribution of the EZ Detect™ product in Asia, Europe and the Middle East.

Walmart to Begin Nationwide In-Store Sales of Biomerica's EZ Detect™ Colorectal Screening Test

IRVINE, Calif., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its first quarter fiscal 2022 financial results.

Biomerica Reports Results for Fiscal First Quarter ended August 31, 2021

The stock price of Biomerica, Inc. (NASDAQ: BMRA) increased by over 19% during intraday trading today. This is why it happened.

BMRA Stock: Why It Increased Drastically Today

Aterian

Progenity

According to Fintel, here are five short squeeze stocks that are among the most likely to see a squeeze attempt moving forward. The post Short Squeeze Stocks: BMRA, PROG and 3 Other Stocks Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: BMRA, PROG and 3 Other Stocks Experts Think Are Ready to Pop

Cellect Biotechnology Ltd

Marin Software

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) and AMC Entertainment Holdings Inc (NYSE: AMC), two stocks that attracted strong interest and saw shares spike. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Aterian, Marin On List Again, Plus 3 New Small-Cap Medical Plays

The stock price of Biomerica, Inc. (NASDAQ: BMRA) increased by 38% in the previous trading session. This is why it happened.

BMRA Stock Price: Why It Increased 38%

Walmart

Biomerica (BMRA) stock is surging higher on Friday thanks to a new deal with Walmart (WMT) concerning its EZ Detect product. The post BMRA Stock: The Big Walmart Deal That Has Biomerica Investors Smiling Today appeared first on InvestorPlace.

BMRA Stock: The Big Walmart Deal That Has Biomerica Investors Smiling Today

Biomerica Inc (NASDAQ:BMRA) has entered into a Supplier Agreement with Walmart Inc (NYSE:WMT) to sell its EZ Detect colorectal disease screening test within the Walmart retail system.  Beginning this week, Walmart has started selling the product through its online sales channel.

Biomerica's Shares Gain As Its Colon Disease Screening Test Goes For Sale At Walmart Online

IRVINE, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that it has entered into a General Merchandise Supplier Agreement with Walmart for the sale of the Company's EZ Detect™ colorectal disease screening test within the Walmart retail system. The Company has now shipped its first orders of the EZ Detect™ product to Walmart, and beginning this week, Walmart has begun selling the product through its online sales channel (https://www.walmart.com/ip/EZ-Detect-Colon-Disease-Test-Kit/577079744).

Walmart Now Selling Biomerica's EZ Detect™ Colorectal Screening Test

Biomerica recently reported its fiscal 2021 Q4 results highlighted by key product updates supporting a positive long-term outlook.

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

IRVINE, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it expects final patient enrollment in its endpoint clinical trial for its InFoods® diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. The clinical trial is being conducted by Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist hospital and the University of Michigan as primary enrollment centers for this study.

Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week

IRVINE, Calif., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2021 financial results. During the year the Company made significant progress in its business by increasing its number of allowed patents covering its InFoods® diagnostic guided therapy technology, signing a distribution agreement for its H. Pylori product which is expected to be filed with FDA in October, 2021, and has entered into negotiations with major retailers/distributors for sales of its EZ Detect colorectal disease test.

Biomerica Reports Fiscal 2021 Year End Results

IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has issued a notice of allowance for Biomerica's first patent pertaining to a revolutionary new treatment option for patients suffering from depression. Specifically, this allowed patent contains broad claims that enables physicians to identify patient specific foods (e.g. salmon, milk, shrimp, broccoli, chickpeas, etc.), that when removed from the patient's diet, may alleviate or improve an individual's depression symptoms.

Biomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression

IRVINE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced the launch of their new website for their EZ Detect™ Colon Disease Test product at https://ezdetect.com. The site features streamlined functionality and easy access to essential and potentially life-saving information about detection and treatment of colorectal diseases including colon cancer. The new site is launching alongside a digital health advertising and social media campaign to promote and drive sales of Biomerica's EZ Detect™ product. The Company is also in discussions with major retailers to increase the U.S. and international distribution of the EZ Detect™ Colon Disease Test by adding the product to their online and in-store offerings.

Biomerica Launches New Website For Its EZ Detect™ Colorectal Disease Screening Test

IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomerica's new and proprietary Helicobacter pylori test, called hp+detect™. The hp+detect™ product has been developed for the identification and monitoring of H. pylori infection, the leading cause of duodenal and gastric ulcers, and a contributing risk factor associated with gastric cancer. Physicians and medical centers can use hp+detect™ to diagnose the presence of H. pylori and to monitor the efficacy of treatment.

Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™

IRVINE, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today announced that the Mexican Patent Office has issued a notice of allowance for Biomerica's patent application pertaining to the Company's InFoods® technology platform that offers a revolutionary approach in the treatment of patients suffering from Irritable Bowel Syndrome (“IBS”). Specifically, this allowed application contains claims that broadly cover the method that enables physicians to identify patient specific foods, such as milk, shrimp, broccoli, etc., that, when removed from the patient's diet, may alleviate or improve an individual's IBS symptoms, including constipation, diarrhea, bloating, severe cramping, pain and indigestion.

Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment

IRVINE, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced that it will be participating in two upcoming investor conferences: the Truist Life Sciences Series and LD Micro Invitational XI event.

Biomerica to Participate in Upcoming Investor Conferences

The stock price of Biomerica, Inc. (NASDAQ: BMRA) increased by over 20% pre-market. This is why it happened.

BMRA Stock: Over 20% Increase Pre-Market Explanation

IRVINE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, announced that its new COVID-19 Antigen Rapid Test can now be performed with a simple less invasive nasal swab. This simple nasal swab, which takes the sample from the front opening of the nose, is less invasive and more comfortable for patients than the deep anterior nasal swab which is typically used. The test is highly portable, cost effective and provides visual results negating the need for any equipment to perform or read the test. The test also provides results in 15 minutes versus lab-run PCR tests which can take up to three days for results, thereby potentially expediting the process of identifying infectious people and preventing further spread of the virus.

Biomerica's Fast 15-Minute Easy to Use COVID-19 Antigen Test Now Available With Simple Nasal Swab

IRVINE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced its fiscal third quarter 2021 financial results for the three months ended February 28, 2021.

News for Biomerica Stock (BMRA)